US2019365682A1PendingUtilityA1
Topical anti-inflammatory compositions
Est. expirySep 16, 2036(~10.2 yrs left)· nominal 20-yr term from priority
A61P 29/00A61K 47/10A61K 47/12A61K 47/36A61K 47/14A61K 9/0014A61K 47/20A61K 31/196A61K 31/192A61K 2121/00A61K 45/06A61K 9/08
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A topical composition includes a non-steroidal anti-inflammatory drug (NSAID) in an aqueous carrier system which contains a cationic galactomannan gum. The carrier system includes, in addition to water and the cationic galactomannan gum, a lactate ester of a C2 to C16 saturated aliphatic alcohol, a monoprotic arylalkanoic acid (pKa 3.8 to 5), a solubility enhancer, and a C2 to C8 saturated aliphatic alcohol.
Claims
exact text as granted — not AI-modified1 . An aqueous, topical anti-inflammatory composition which comprises
a non-steroidal anti-inflammatory drug (NSAID) which is an arylalkanoic acid, a lactate ester of a C 2 to C 16 saturated aliphatic alcohol, a monoprotic organic acid having a pKa value in the range of about 3.8 to about 5, a C 2 to C 8 saturated aliphatic alcohol, a solubility enhancer, and a cationic galactomannan gum.
2 . The anti-inflammatory composition in accordance with claim 1 wherein the arylalkanoic acid is an arylethanoic acid.
3 . The anti-inflammatory composition in accordance with claim 2 wherein the arylethanoic acid is diclofenac.
4 . The anti-inflammatory composition in accordance with claim 2 wherein the arylethanoic acid is diclofenac sodium.
5 . The anti-inflammatory composition in accordance with claim 2 wherein the arylethanoic acid is diclofenac diethylamine.
6 . The anti-inflammatory composition in accordance with claim 1 wherein the arylalkanoic acid is an arylpropanoic acid.
7 . The anti-inflammatory composition in accordance with claim 6 wherein the arylpropanoic acid is naproxen.
8 . The anti-inflammatory composition in accordance with claim 6 wherein the arylpropanoic acid is naproxen sodium.
9 . The anti-inflammatory composition in accordance with claim 6 wherein the arylpropanoic acid is ibuprofen.
10 . The anti-inflammatory composition in accordance with claim 6 wherein the arylpropanoic acid is ketoprofen.
11 . The anti-inflammatory composition in accordance with claim 1 wherein the C 2 to C 8 saturated aliphatic alcohol is a monohydric alcohol.
12 . The anti-inflammatory composition in accordance with claim 11 wherein the monohydric alcohol is ethanol.
13 . The anti-inflammatory composition in accordance with claim 1 wherein the C 2 to C 8 saturated aliphatic alcohol is a dihydric alcohol.
14 . The anti-inflammatory composition in accordance with claim 1 wherein the monoprotic organic acid has a pKa value in the range of about 4.6 to about 4.8.
15 . The anti-inflammatory composition in accordance with claim 1 wherein the cationic galactomannan gum is a cationic guar gum with hydroxypropyl-trimethylammonium groups.
16 . The anti-inflammatory composition in accordance with claim 15 wherein the cationic guar gum is guar gum, 2-hydroxy-3-(trimethylammonium) propyl ether chloride.
17 . The anti-inflammatory composition in accordance with claim 1 wherein the lactate ester is lauryl lactate.
18 . The anti-inflammatory composition in accordance with claim 1 wherein the solubility enhancer is glycerol monolaurate.
19 . The anti-inflammatory composition in accordance with claim 1 further including a photostabilizer.
20 . The anti-inflammatory composition in accordance with claim 19 wherein the photostabilizer is sulisobenzone.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.